SELLAS Life Sciences Group (SLS) Expected to Announce Quarterly Earnings on Thursday

Key Points

• SELLAS (NASDAQ:SLS) is expected to report Q4 2025 results before the market opens on March 19, 2026; analysts forecast a loss of ($0.0633) per share and the company has an earnings call scheduled for March 18 at 4:00 PM ET.
• SLS traded around $5.48 with a 52-week range of $0.95–$6.14 and a market cap of ~$780.6M; the stock has a negative PE (-19.57) and 50/200-day moving averages of $4.30/$2.74.
• Market sentiment is mixed — the consensus rating is Hold with a $7.00 price target while Weiss Ratings reissued a sell (d-) — SELLAS is a clinical-stage biotech developing a WT1-targeted peptide vaccine, lead candidate galinpepimut-S (GPS).

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) will likely be posting its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.0633) per share for the quarter. Investors may review the information on the company's upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 18, 2026 at 4:00 PM ET.

SELLAS Life Sciences Group Stock Performance

SLS opened at $5.48 on Thursday. SELLAS Life Sciences Group has a one year low of $0.95 and a one year high of $6.14. The stock has a market capitalization of $780.58 million, a PE ratio of -19.57 and a beta of 2.18. The business's 50 day moving average price is $4.30 and its 200 day moving average price is $2.74.

Institutional Investors Weigh In On SELLAS Life Sciences Group

A number of institutional investors have recently made changes to their positions in SLS. BNP Paribas Financial Markets lifted its holdings in shares of SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company's stock worth $32,000 after acquiring an additional 9,299 shares during the last quarter. Beacon Pointe Advisors LLC purchased a new position in shares of SELLAS Life Sciences Group during the 4th quarter worth approximately $38,000. Sei Investments Co. acquired a new stake in SELLAS Life Sciences Group in the 3rd quarter valued at approximately $43,000. Great Valley Advisor Group Inc. purchased a new stake in SELLAS Life Sciences Group in the second quarter valued at approximately $44,000. Finally, Equitable Holdings Inc. raised its position in SELLAS Life Sciences Group by 58.6% in the third quarter. Equitable Holdings Inc. now owns 27,060 shares of the company's stock valued at $44,000 after purchasing an additional 10,000 shares during the period. 17.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of SELLAS Life Sciences Group in a research note on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, SELLAS Life Sciences Group currently has an average rating of "Hold" and a consensus price target of $7.00.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms' tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient's own immune system to recognize and attack WT1-positive cancer cells.

The company's lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.